GLP-1 Market
LLY $1283.66 ▲ +3.5% NVO $39.35 ▲ +2.4% PFE $30.11 ▲ +2.3% VKTX $26.71 ▲ +6.6% KLRA $12.89 ▲ +12.8% GPCR $22.88 ▲ +4.0% RHHBY $59.11 ▲ +3.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AlloRx

Company
The Foundation for Orthopaedics and Regenerative Medicine
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 21, 2026

Find a Clinical Trial Near Me

See recruiting studies for AlloRx and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05147675

    Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for OA

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine 92 participants Est. completion 2027-12-01 2 sites Stand-alone
    Osteoarthritis Other conditions: Spinal Arthritis
    View official trial listing →
  • Terminated NCT NCT05003908

    Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Diabetes

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine 2 participants Est. completion 2025-04-04 2 sites Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Terminated NCT NCT05016804

    Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine 20 participants Est. completion 2025-11-30 2 sites Stand-alone
    Other conditions: Systemic Sclerosis
    View official trial listing →
  • Terminated NCT NCT05016817

    Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine 20 participants Est. completion 2025-11-30 1 site Stand-alone
    Other conditions: Idiopathic Pulmonary Fibrosis
    View official trial listing →
  • Terminated NCT NCT05018845

    Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CKD

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine 20 participants Est. completion 2025-11-30 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Terminated NCT NCT05147766

    Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine 3 participants Est. completion 2025-04-03 2 sites Stand-alone
    Heart failure Other conditions: Angina
    View official trial listing →
  • Terminated NCT NCT05147779

    Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine 20 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Erectile Dysfunction, Peyronie's Disease, Interstitial Cystitis
    View official trial listing →
  • Withdrawn NCT NCT05152381

    Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Osteoporosis

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine Est. completion 2025-04-04 1 site Stand-alone
    Other conditions: Osteoporosis
    View official trial listing →
  • Withdrawn NCT NCT05158114

    Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine Est. completion 2025-04-03 1 site Stand-alone
    Other conditions: Testicular Injury, Oligospermia
    View official trial listing →
  • Withdrawn NCT NCT05158933

    Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Ovarian Failure

    Not yet reported The Foundation for Orthopaedics and Regenerative Medicine Est. completion 2025-04-03 1 site Stand-alone
    Other conditions: Ovarian Failure
    View official trial listing →
  • Status unknown NCT NCT05165017

    Safety & Efficacy of AlloRx SC® in PTHS Patients

    Not yet reported, Not yet reported Vitro Biopharma Inc. 26 participants Est. completion 2023-12
    Other conditions: Pitt Hopkins Syndrome
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.